Giganteone A and malabaricone C as potential pharmacotherapy for diabetes mellitus
Document Type
Article
Publication Date
3-19-2022
Abstract
The use of antidiabetic agents which control glycemic levels in the blood and simultaneously inhibit oxidative stress is an important strategy in the prevention of Diabetes Mellitus and its complications. In our previous study, malabaricone C (3) and its dimer, giganteone A (5) exhibited significant DPPH free radical scavenging activities which were lower than the activity of the positive control, ascorbic acid. These compounds were evaluated for their alpha-glucosidase inhibitory activities at different concentrations (0.02-2.5 mM) in the present study. Compounds 3 (IC50 59.61 mu M) and 5 (IC50 39.52 mu M) were identified as active alpha-glucosidase inhibitors, each respectively being 24 and 37 folds more potent than the standard inhibitor, acarbose. Based on the molecular docking studies, compounds 3 and 5 docked into the active site of the alpha-glucosidase enzyme, forming mainly hydrogen bonds in the active site.
Keywords
Myristica cinnamomea King, Giganteone A, Malabaricone C, Malabaricone E, α, -glucosidase inhibitory activity
Divisions
Science,pharmacy
Funders
Ministry of Education, Malaysia [Grant No: FP002-2018A],Universiti Malaya [Grant No: RP001-2012 & BK002-2015]
Publication Title
Natural Product Research
Volume
36
Issue
6
Publisher
Taylor & Francis
Publisher Location
2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND